Clostridium difficile - A moving target

F1000 Medicine Reports

Volumn 3, Issue 1, 2011, Pages

  Tillotson, Glenn S ^a   Tillotson, Joni ^b  

^a Optimer Pharmaceuticals Inc   (United States)

^b IMMACULATA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE; CLOSTRIDIUM DIFFICILE VACCINE; FIDAXOMICIN; METRONIDAZOLE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN;

ANTIBIOTIC THERAPY; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG RESEARCH; HUMAN; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; RECURRENT DISEASE; REVIEW;

EID: 79955695737     PISSN: None     EISSN: 17575931     Source Type: Journal    
DOI: 10.3410/M3-6     Document Type: Review

References (23)

1. Henrich TJ, Krakower D, Bitton A, Yokoe DS: Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 2009, 15:415-22.
2. Pépin JL, Valiquette L, Abary ME, Villemure P, Pelletier A, Forget K, Pépin K, Chouinard D: Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 2004, 171:466-72.
3. McDonald LC, Killgore GE, Thompson A, Owens RC Jr, Kazakova SV, Sambol SP, Johnson S, Gerding DN: An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005, 353:2433-41. F1000 Factor 10 Evaluated by Jon Markowitz 16 Dec 2005
4. McDonald LC, Owings M, Jernigan DB: Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis 2006, 12:409-15.
5. Hudson M: Statistical bulletin-Deaths involving Clostridium difficile: England & Wales, 2009. Newport, Wales: Office for National Statistics; 2010.
6. Freeman J, Bauer MP, Baines SD, Corver J, Fawley WN, Goorhuis B, Kuijper EJ, Wilcox MH: The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 2010, 23:529-49.
7. Clements AC, Magalhães RJ, Tatern AJ, Paterson DL, Riley TV: Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Inf Dis 2010, 10:395-404.
8. Songer JG: Clostridia as agents of zoonotic disease. Vet Microbiol 2010, 140:399-404.
9. Zilberberg MD, Tillotson GS, McDonald C: Clostridium difficile infections among hospitalized children, United Sates, 1997-2006. Emerg Infect Dis 2010, 16:604-9.
10. O'Brien JA, Lahue BJ, Caro JJ, Davidson DM: The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol 2007, 28:1219-27. (Pubitemid 47596558)
11. Lyras D, O'Connor JR, Howarth PM, Sambol SP, Carter GP, Phumoonna T, Poon R, Adams V, Vedantam G, Johnson S, Gerding DN, Rood JI: Toxin B is essential for virulence of Clostridium difficile. Nature 2009, 458:1176-9. F1000 Factor 10 Evaluated by Tor Savidge 18 Mar 2009
12. Kuehne SA, Cartman ST, Heap JT, Kelly ML, Cockayne A, Minton NP: The role of toxin A and toxin B in Clostridium difficile infection. Nature 2010, 467:711-3.
13. Merrigan M, Venugopal A, Mallozzi M, Roxas B, Viswanathan VK, Johnson S, Gerding DN, Vedantam G: Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 2010, 192:4904-11.
14. Dang TH, de la Riva L, Fagan RP, Storck EM, Heal WP, Janoir C, Fairweather NF, Tate EW: Chemical probes of surface layer biogenesis in Clostridium difficile. ACS Chem Biol 2010, 5:279-85. F1000 Factor 8 Evaluated by Matthew Bogyo 17 Sep 2010
15. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, Pepin J, Wilcox MH; Society for Healthcare Epidemiology of America; Infectious Diseases Society of America: Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Disease Society of America (IDSA). Infect Control Hosp Epidemiolol 2010, 31:431-55.
16. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB: A comparison of vancomcyin and metronidazole for the treatement of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007, 45:302-7. F1000 Factor 9 Evaluated by Larry Bush 07 Aug 2007, John Heritage 25 Oct 2007
17. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. September 17-20, 2007; Chicago, IL. Washington, DC: ASM Press; 2007.
18. Miller M, Bernard L, Thompson M, Grima D, Pepin J: Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol 2010, 31:710-5. F1000 Factor 6 Evaluated by Stephen Weber 21 Sep 2010
19. Gerding DN: Metronidazole for Clostridium difficile-associated disease: is it okay for Mom? Clin Infect Dis 2005, 40:1598-600.
20. th Annual Conference of the Infectious Disease Society of America, October 21-24, 2010, Vancouver, Canada.
21. Lowy I, Molrine DC, Leav BA, Blair BM, Baxter R, Gerding DN, Nichol G, Thomas WD Jr, Leney M, Sloan S, Hay CA, Ambrosino DM: Treatment with monoclonal antibodies against Clostridium difficile toxins. New Engl J Med 2010, 362:197-205. F1000 Factor 12 Evaluated by Ian Beales 26 Jan 2010, Daniel Remick 23 Feb 2010
22. th Anaerobe Society of the Americas, July 7-10, 2010; Philadelphia, PA.
23. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12-15, 2010; Boston, MA. Washington, DC: ASM Press; 2010.